Literature DB >> 18753428

Assay validation and biological variation of serum receptor for advanced glycation end-products.

Louise F Brown1, Callum G Fraser.   

Abstract

BACKGROUND: The analytical performance characteristics of an enzyme-linked immunosorbent assay for the receptor for advanced glycation end-products (RAGE) were evaluated. The within- and between-subject components of biological variation were also estimated.
METHODS: Blood was sampled from healthy volunteers into K(2)-ethylenediamine tetraacetic acid (EDTA) and serum separator tubes (SST) and the stability of RAGE in whole blood, plasma and serum examined. Performance characteristics of the assay were assessed using quality control materials. Three samples were obtained from each of 21 healthy volunteers one-week apart, RAGE measured and components of biological variation estimated.
RESULTS: RAGE concentrations in blood specimens collected into K(2)-EDTA and SST were stable for at least 6 hours and, after centrifugation, both plasma and serum were stable for at least 24 hours. The RAGE assay had the following characteristics: inter-assay imprecision: coefficient of variation </=7.3%, working range: 26-5000 ng/L, linearity: r = 0.9977 and detection limit: 26 ng/L. Overall within- and between-subject biological variations were 14.6% and 56.5%, the index of individuality was 0.31 and the reference change value was 49.0% at P < 0.05.
CONCLUSION: Samples for RAGE analyses in serum or plasma can be collected without significant difficulties with the assay showing acceptable analytical performance characteristics. Conventional population-based reference values are of limited utility in diagnosis, indicating that RAGE is likely to be more useful in monitoring disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753428     DOI: 10.1258/acb.2008.008043

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  7 in total

1.  Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study.

Authors:  Casey M Rebholz; Brad C Astor; Morgan E Grams; Marc K Halushka; Mariana Lazo; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Elizabeth Selvin
Journal:  Nephrol Dial Transplant       Date:  2014-08-21       Impact factor: 5.992

2.  Patterns of salivary analytes provide diagnostic capacity for distinguishing chronic adult periodontitis from health.

Authors:  Jeffrey L Ebersole; Julie L Schuster; Jason Stevens; Dolph Dawson; Richard J Kryscio; Yushin Lin; Mark V Thomas; Craig S Miller
Journal:  J Clin Immunol       Date:  2012-08-29       Impact factor: 8.317

3.  Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene.

Authors:  Anastasia Z Kalea; Nina Reiniger; Hojin Yang; Maria Arriero; Ann Marie Schmidt; Barry I Hudson
Journal:  FASEB J       Date:  2009-01-22       Impact factor: 5.191

Review 4.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Authors:  Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
Journal:  J Transl Med       Date:  2009-03-17       Impact factor: 5.531

Review 5.  The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?

Authors:  Benedict C Creagh-Brown; Gregory J Quinlan; Timothy W Evans; Anne Burke-Gaffney
Journal:  Intensive Care Med       Date:  2010-07-15       Impact factor: 17.440

6.  Evaluation of method performance for oxidative stress biomarkers in urine and biological variations in urine of patients with type 2 diabetes mellitus and diabetic nephropathy.

Authors:  Ergul Belge Kurutas; Yakup Gumusalan; Ali Cetinkaya; Ekrem Dogan
Journal:  Biol Proced Online       Date:  2015-02-02       Impact factor: 3.244

7.  Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients.

Authors:  Tarek Mk Motawi; Mohamed A Abou-Seif; Ahmed Ma Bader; Mohamed O Mahmoud
Journal:  BMC Endocr Disord       Date:  2013-08-21       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.